产品
编 号：F255176
分子式：C16H20O9
分子量：356.32
分子式：C16H20O9
分子量：356.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
175
In-stock
5mg
350
In-stock
10mg
560
In-stock
25mg
1120
In-stock
50mg
1920
In-stock
100mg
2960
In-stock
结构图
CAS No: 20831-76-9
产品详情
生物活性：
Gentiopicroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC50 and a Ki of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has anti-inflammatoryand antioxidative effects.
体内研究：
Gentiopicroside (20, 40, and 80 mg/kg, p.o.) significantly reduces gastric ulcerindex in mice. Gentiopicroside (20, 40, and 80 mg/kg) also ovbiously decreases the levels of HSP-70, TNF-α, IL-6, MDA and increases ncreased GSH level and SOD activity. In addition, Gentiopicroside normalizes EGF and VEGF level in mice.
体外研究：
Gentiopicroside inhibits P450 activity, with an IC50 and a Ki of 61 μM and 8.12 μM for CYP2A6, also slightly inhibits CYP2E1 activity with an IC50 of 1.6 mM, but shows no inhibition on CYP1A2 and CYP3A4. Gentiopicroside (12.5, 25 and 50?μM) inhibits RANKL-induced osteoclast formation from mouse bone marrow macrophages (BMMs) in a dose-dependent manner, blocks the expression of osteoclast-related proteins, prevents receptor activator of nuclear factor-κB ligand (RANKL)-triggered JNK and NF-κB activation. Gentiopicroside (50?μM) also inhibits RANKL-induced bone resorption.
Gentiopicroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC50 and a Ki of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has anti-inflammatoryand antioxidative effects.
体内研究：
Gentiopicroside (20, 40, and 80 mg/kg, p.o.) significantly reduces gastric ulcerindex in mice. Gentiopicroside (20, 40, and 80 mg/kg) also ovbiously decreases the levels of HSP-70, TNF-α, IL-6, MDA and increases ncreased GSH level and SOD activity. In addition, Gentiopicroside normalizes EGF and VEGF level in mice.
体外研究：
Gentiopicroside inhibits P450 activity, with an IC50 and a Ki of 61 μM and 8.12 μM for CYP2A6, also slightly inhibits CYP2E1 activity with an IC50 of 1.6 mM, but shows no inhibition on CYP1A2 and CYP3A4. Gentiopicroside (12.5, 25 and 50?μM) inhibits RANKL-induced osteoclast formation from mouse bone marrow macrophages (BMMs) in a dose-dependent manner, blocks the expression of osteoclast-related proteins, prevents receptor activator of nuclear factor-κB ligand (RANKL)-triggered JNK and NF-κB activation. Gentiopicroside (50?μM) also inhibits RANKL-induced bone resorption.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备